ARCH Venture Management, LLC
13F Reported Value
ⓘ$677.1M
Holdings
10
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
ARCH Venture Management, LLC disclosed 10 positions worth $677.1M in its Form 13F-HR for Q1 2026, led by $MAZE (Maze Therapeutics, Inc.) at 18.2% of the equity portfolio, followed by $RAPP and $VIR. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $GENB. The portfolio is most concentrated in Healthcare (99.3% of disclosed assets). All figures are sourced directly from ARCH Venture Management, LLC’s Form 13F-HR filing with the SEC under CIK 1274403.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 19.7#2,687
Quality
$123.0M4,120,053 sh - —
Quality
$116.7M3,728,738 sh - 5.6#2,846
Quality
$115.7M12,916,663 sh - —
Quality
$114.7M7,091,557 sh - 12.1
Quality
$108.2M4,540,132 sh - 3.6
Quality
$65.1M3,247,162 sh - —
Quality
$24.3M1,944,426 sh - 44.1
Quality
$4.6M217,834 sh - 27.1
Quality
$2.6M8,055,916 sh - 23.1
Quality
$2.1M320,482 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Maze Therapeutics, Inc.$MAZE | 19.7#2,687 | $123.0M | 4,120,053 |
 Rapport Therapeutics, Inc.$RAPP | — | $116.7M | 3,728,738 |
 Vir Biotechnology, Inc.$VIR | 5.6#2,846 | $115.7M | 12,916,663 |
 Erasca, Inc.$ERAS | — | $114.7M | 7,091,557 |
 Beam Therapeutics Inc.$BEAM | 12.1 | $108.2M | 4,540,132 |
 Lyell Immunopharma, Inc.$LYEL | 3.6 | $65.1M | 3,247,162 |
 Generate Biomedicines, Inc.$GENB | — | $24.3M | 1,944,426 |
 10x Genomics, Inc.$TXG | 44.1 | $4.6M | 217,834 |
 Gossamer Bio, Inc.$GOSS | 27.1 | $2.6M | 8,055,916 |
 Q32 Bio Inc.$QTTB | 23.1 | $2.1M | 320,482 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of ARCH Venture Management, LLC's 10 positions.
Showing top 10 of 10 holdings.
Sector Allocation
Healthcare
$672.5M
Technology
$4.6M
Full Holdings — ARCH Venture Management, LLC (Q1 2026)
All 10 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MAZE | Maze Therapeutics, Inc. | $123.0M | 18.2% | +0% | 19.7 |
| 2 | $RAPP | Rapport Therapeutics, Inc. | $116.7M | 17.2% | +0% | — |
| 3 | $VIR | Vir Biotechnology, Inc. | $115.7M | 17.1% | +0% | 5.6 |
| 4 | $ERAS | Erasca, Inc. | $114.7M | 16.9% | -36% | — |
| 5 | $BEAM | Beam Therapeutics Inc. | $108.2M | 16.0% | +0% | 12.1 |
| 6 | $LYEL | Lyell Immunopharma, Inc. | $65.1M | 9.6% | +18% | 3.6 |
| 7 | $GENB | Generate Biomedicines, Inc. | $24.3M | 3.6% | NEW | — |
| 8 | $TXG | 10x Genomics, Inc. | $4.6M | 0.7% | -70% | 44.1 |
| 9 | $GOSS | Gossamer Bio, Inc. | $2.6M | 0.4% | +0% | 27.1 |
| 10 | $QTTB | Q32 Bio Inc. | $2.1M | 0.3% | +0% | 23.1 |
New Positions (1)
$GENB Generate Biomedicines, Inc.$24.3MBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for ARCH Venture Management, LLC including:
Track ARCH Venture Management, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for ARCH Venture Management, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: ARCH Venture Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For ARCH Venture Management, LLC (SEC CIK: 1274403), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in ARCH Venture Management, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.